Listen to our 'Targeting diabetes' podcast now
23 Nov 2018
Glucose-lowering medications have been the mainstay of managing type 2 diabetes for 20 years, but in April this year a polemic erupted around specific targets for blood sugar. The American College of Physician recommended less stringent control than had been previously accepted, and invoked fierce criticism from other diabetes organisations around the world.
It all comes down to the interpretation of four key trials between designed to show a link between intensive glycemic control and improvement in cardiovascular symptoms. On this podcast, Dr Paul Drury and Professor Sophia Zoungas help make sense of the inconsistencies between the findings and explain how these inform individualised strategies for patients with different histories.
In recent years there have also been trials of new drug classes that don’t just lower blood glucose but appear to provide cardiovascular benefits directly in sicker patients. These are the SGLT2 inhibitors and GLP-1 receptor agonists, and we’ll summarise the use advised in a very recent consensus statement.
Professor Sophia Zoungas FRACP (Monash Health; Board Director, Diabetes Australia; Clinical Director, National Association of Diabetes Centres).
- Dr Paul Drury FRACP (Clinical Advisor in Diabetes, NZ Ministry of Health).
RACP Fellows can claim CPD credits via MyCPD for listening and using resources related to this episode. Subscribe to Pomegranate Health within Apple iTunes, Spotify or any Android podcasting app.
We are recruiting a podcast editorial group for 2019.
The group will help maintain the high standards of the podcasts. This involves discussing of new topics, suggesting expert contacts to interview, and reviewing audio drafts to provide feedback before they are published. This is all done by email and can contribute to your CPD credits. You can complete an expression of interest at this link and return to email@example.com. Please share with anyone who might be interested.